8-K Announcements
6Material company update
Feb 27, 2026·SEC
Material company update
Feb 19, 2026·SEC
Material company update
Dec 30, 2025·SEC
Tandem Diabetes Care, Inc.(TNDM)Earnings, Financials & Key Ratios
TNDM•NASDAQ
$18.03
$1.24B mkt cap·Price updated May 6, 2026
AboutTandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.Show more
- Revenue$1.01B+7.9%
- EBITDA-$60M+38.9%
- Net Income-$205M-113.2%
- EPS (Diluted)-3.04-106.8%
- Gross Margin52.31%+0.5%
- EBITDA Margin-5.96%+43.4%
- Operating Margin-7.7%+27.0%
- Net Margin-20.17%-97.5%
- ROE-97.88%-193.9%
- ROIC-9.96%+10.4%
- Debt/Equity2.86+59.1%
- Interest Coverage-24.33-81.7%
TNDM Key Insights
Tandem Diabetes Care, Inc. (TNDM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 15.3%
- ✓Efficient asset utilization: 1.2x turnover
✗Weaknesses
- ✗High debt to equity ratio of 2.9x
- ✗Profits declining 42.9% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TNDM Price & Volume
Tandem Diabetes Care, Inc. (TNDM) stock price & volume — 10-year historical chart
Loading chart...
TNDM Growth Metrics
Tandem Diabetes Care, Inc. (TNDM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years30.13%
5 Years15.26%
3 Years8.19%
TTM-4.23%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-113.18%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-110.39%
Return on Capital
10 Years-29.38%
5 Years-12.24%
3 Years-17.76%
Last Year-11.5%
TNDM Recent Earnings
Tandem Diabetes Care, Inc. (TNDM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 6/12 qtrs (50%)
Q1 2026Latest
Feb 19, 2026EPS
$0.01
Est $0.05
+80.0%
Revenue
$290M
Est $277M
+4.8%
Q4 2025
Nov 6, 2025EPS
$0.31
Est $0.31
+0.0%
Revenue
$249M
Est $277M
-10.0%
Q3 2025
Aug 6, 2025EPS
$0.48
Est $0.40
-20.0%
Revenue
$241M
Est $250M
-3.8%
Q2 2025
Apr 30, 2025EPS
$0.67
Est $0.60
-11.7%
Revenue
$234M
Est $220M
+6.5%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 19, 2026 | $0.01vs $0.05+80.0% | $290Mvs $277M+4.8% |
| Q4 2025 | Nov 6, 2025 | $0.31vs $0.31+0.0% | $249Mvs $277M-10.0% |
| Q3 2025 | Aug 6, 2025 | $0.48vs $0.40-20.0% | $241Mvs $250M-3.8% |
| Q2 2025 | Apr 30, 2025 | $0.67vs $0.60-11.7% | $234Mvs $220M+6.5% |
Based on last 12 quarters of dataView full earnings history →
TNDM Peer Comparison
Tandem Diabetes Care, Inc. (TNDM) competitors in Diabetes care and insulin delivery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PODD | 10.61B | 151.17 | 43.44 | 30.73% | 10.44% | 21.38% | 0.69 | |
 DXCM | 23.29B | 60.36 | 28.88 | 15.6% | 19.31% | 33.83% | 0.51 | |
 ABBV | 362.56B | 204.98 | 86.49 | 8.57% | 6.91% | 62.15% | ||
 MDT | 99.48B | 77.60 | 21.50 | 3.62% | 13% | 9.45% | 0.59 | |
 NVO | 203.36B | 45.76 | 12.65 | 6.43% | 33.14% | 61.1% | 0.67 | |
 LLY | 932.64B | 987.11 | 43.01 | 44.7% | 34.98% | 101.17% | 1.60 | |
 SANA | 954.64M | 3.64 | -3.14 | -120.02% | 0.38 | |||
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 |
Compare TNDM vs Peers
Tandem Diabetes Care, Inc. (TNDM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TNDM Income Statement
Tandem Diabetes Care, Inc. (TNDM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 107.6M | 183.87M | 362.31M | 498.83M | 702.8M | 801.22M | 747.72M | 940.2M | 1.01B |
| Revenue Growth % | 27.72% | 70.88% | 97.05% | 37.68% | 40.89% | 14% | -6.68% | 25.74% | 7.93% |
| Cost of Goods Sold | 63.51M | 94.04M | 168.09M | 238.31M | 326.58M | 388.23M | 380.03M | 450.63M | 483.89M |
| COGS % of Revenue | 59.02% | 51.15% | 46.4% | 47.77% | 46.47% | 48.46% | 50.82% | 47.93% | 47.69% |
| Gross Profit | 44.09M▲ 0% | 89.82M▲ 103.7% | 194.21M▲ 116.2% | 260.52M▲ 34.1% | 376.21M▲ 44.4% | 412.99M▲ 9.8% | 367.69M▼ 11.0% | 489.57M▲ 33.1% | 530.85M▲ 8.4% |
| Gross Margin % | 40.98% | 48.85% | 53.6% | 52.23% | 53.53% | 51.54% | 49.18% | 52.07% | 52.31% |
| Gross Profit Growth % | 86.9% | 103.71% | 116.22% | 34.14% | 44.41% | 9.77% | -10.97% | 33.15% | 8.43% |
| Operating Expenses | 107.04M | 134.45M | 210.93M | 268.48M | 353.56M | 505.83M | 600.92M | 588.7M | 608.97M |
| OpEx % of Revenue | 99.48% | 73.13% | 58.22% | 53.82% | 50.31% | 63.13% | 80.37% | 62.61% | 60.01% |
| Selling, General & Admin | 86.38M | 105.23M | 165.74M | 204.9M | 261.51M | 335.68M | 352.5M | 389.82M | 434.13M |
| SG&A % of Revenue | 80.28% | 57.23% | 45.74% | 41.08% | 37.21% | 41.9% | 47.14% | 41.46% | 42.78% |
| Research & Development | 20.66M | 29.23M | 45.2M | 63.57M | 92.05M | 170.15M | 248.42M | 198.88M | 174.84M |
| R&D % of Revenue | 19.2% | 15.9% | 12.48% | 12.74% | 13.1% | 21.24% | 33.22% | 21.15% | 17.23% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -62.94M▲ 0% | -44.63M▲ 29.1% | -16.72M▲ 62.5% | -7.96M▲ 52.4% | 22.65M▲ 384.7% | -92.85M▼ 509.9% | -233.23M▼ 151.2% | -99.13M▲ 57.5% | -78.12M▲ 21.2% |
| Operating Margin % | -58.5% | -24.27% | -4.62% | -1.6% | 3.22% | -11.59% | -31.19% | -10.54% | -7.7% |
| Operating Income Growth % | 19.36% | 29.09% | 62.53% | 52.42% | 384.69% | -509.87% | -151.2% | 57.5% | 21.19% |
| EBITDA | -56.08M | -38.81M | -10.65M | 2.49M | 36.5M | -78.52M | -217.51M | -98.97M | -60.46M |
| EBITDA Margin % | -52.12% | -21.11% | -2.94% | 0.5% | 5.19% | -9.8% | -29.09% | -10.53% | -5.96% |
| EBITDA Growth % | 22.72% | 30.79% | 72.56% | 123.42% | 1363.43% | -315.13% | -177.03% | 54.5% | 38.91% |
| D&A (Non-Cash Add-back) | 6.87M | 5.82M | 6.07M | 10.45M | 13.85M | 14.33M | 15.71M | 158K | 17.67M |
| EBIT | -61.68M | -115M | -24.53M | -23.48M | 20.21M | -88.54M | -212.18M | -99.28M | -192.37M |
| Net Interest Income | -11.1M | -6.12M | 3.19M | -11.24M | -5.37M | -151K | 12.98M | 10.58M | 1.18M |
| Interest Income | 239K | 1.46M | 3.27M | 1.57M | 674K | 6.06M | 22.86M | 17.99M | 9.09M |
| Interest Expense | 11.34M | 7.58M | 78K | 12.8M | 6.04M | 6.21M | 9.88M | 7.42M | 7.91M |
| Other Income/Expense | -10.08M | -77.93M | -7.88M | -28.32M | -6.75M | -4K | 12.98M | 7.26M | -122.15M |
| Pretax Income | -73.03M▲ 0% | -122.56M▼ 67.8% | -24.6M▲ 79.9% | -36.28M▼ 47.5% | 15.9M▲ 143.8% | -92.85M▼ 683.9% | -220.25M▼ 137.2% | -91.87M▲ 58.3% | -200.27M▼ 118.0% |
| Pretax Margin % | -67.87% | -66.66% | -6.79% | -7.27% | 2.26% | -11.59% | -29.46% | -9.77% | -19.74% |
| Income Tax | 8K | 51K | 149K | -1.9M | 335K | 1.74M | 2.36M | 4.16M | 4.44M |
| Effective Tax Rate % | -0.01% | -0.04% | -0.61% | 5.24% | 2.11% | -1.88% | -1.07% | -4.52% | -2.22% |
| Net Income | -73.03M▲ 0% | -122.61M▼ 67.9% | -24.75M▲ 79.8% | -34.38M▼ 38.9% | 15.57M▲ 145.3% | -94.59M▼ 707.7% | -222.61M▼ 135.3% | -96.03M▲ 56.9% | -204.71M▼ 113.2% |
| Net Margin % | -67.87% | -66.69% | -6.83% | -6.89% | 2.21% | -11.81% | -29.77% | -10.21% | -20.17% |
| Net Income Growth % | 12.48% | -67.88% | 79.81% | -38.9% | 145.27% | -707.7% | -135.33% | 56.86% | -113.18% |
| Net Income (Continuing) | -73.03M | -122.61M | -24.75M | -34.38M | 15.57M | -94.59M | -222.61M | -96.03M | -204.71M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -12.86▲ 0% | -2.55▲ 80.2% | -0.42▲ 83.5% | -0.56▼ 33.3% | 0.24▲ 142.9% | -1.47▼ 712.5% | -3.43▼ 133.3% | -1.47▲ 57.1% | -3.04▼ 106.8% |
| EPS Growth % | 52.89% | 80.17% | 83.53% | -33.33% | 142.86% | -712.5% | -133.33% | 57.14% | -106.8% |
| EPS (Basic) | -12.86 | -2.55 | -0.42 | -0.56 | 0.25 | -1.47 | -3.43 | -1.47 | -3.04 |
| Diluted Shares Outstanding | 5.68M | 48.13M | 58.51M | 60.99M | 64.35M | 64.15M | 64.97M | 65.45M | 67.28M |
| Basic Shares Outstanding | 5.68M | 48.13M | 58.51M | 60.99M | 63M | 64.15M | 64.9M | 65.45M | 67.28M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
TNDM Balance Sheet
Tandem Diabetes Care, Inc. (TNDM) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 64.16M | 187.88M | 276.14M | 637.24M | 811.52M | 849.98M | 747.99M | 724.49M | 618.14M |
| Cash & Short-Term Investments | 14.18M | 129.03M | 176.46M | 484.94M | 623.81M | 616.9M | 467.91M | 438.33M | 292.67M |
| Cash Only | 13.7M | 41.83M | 51.17M | 94.61M | 71.18M | 172.52M | 58.87M | 69.23M | 90.63M |
| Short-Term Investments | 479K | 87.2M | 125.28M | 390.32M | 552.63M | 444.38M | 409.04M | 369.1M | 202.03M |
| Accounts Receivable | 20.79M | 35.19M | 46.59M | 82.19M | 110.72M | 114.72M | 105.56M | 114.58M | 165.49M |
| Days Sales Outstanding | 70.53 | 69.86 | 46.93 | 60.14 | 57.51 | 52.26 | 51.53 | 44.48 | 59.53 |
| Inventory | 26.99M | 19.9M | 49.07M | 63.72M | 68.55M | 111.12M | 157.94M | 149.61M | 128.77M |
| Days Inventory Outstanding | 155.14 | 77.22 | 106.56 | 97.6 | 76.61 | 104.47 | 151.69 | 121.18 | 97.13 |
| Other Current Assets | 2.19M | 3.77M | 0 | 0 | 0 | 7.24M | 16.59M | 21.96M | 31.22M |
| Total Non-Current Assets | 31.19M | 18.41M | 49.97M | 79.18M | 93.62M | 202.81M | 204.67M | 243.17M | 262.97M |
| Property, Plant & Equipment | 19.63M | 17.15M | 48.48M | 69.8M | 77.89M | 179.18M | 164.33M | 163.46M | 179.75M |
| Fixed Asset Turnover | 5.48x | 10.72x | 7.47x | 7.15x | 9.02x | 4.47x | 4.55x | 5.75x | 5.65x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.46M | 1.13M | 777K | 8.8M | 6.64M | 4.63M | 2.78M | 925K | 0 |
| Long-Term Investments | 10M | 0 | 0 | 0 | 0 | 0 | 0 | 74.55M | 60.35M |
| Other Non-Current Assets | 10.1M | 128K | 708K | 580K | 9.09M | 19M | 37.56M | 4.24M | 22.87M |
| Total Assets | 95.35M▲ 0% | 206.29M▲ 116.4% | 326.11M▲ 58.1% | 716.41M▲ 119.7% | 905.14M▲ 26.3% | 1.05B▲ 16.3% | 952.66M▼ 9.5% | 967.66M▲ 1.6% | 881.11M▼ 8.9% |
| Asset Turnover | 1.13x | 0.89x | 1.11x | 0.70x | 0.78x | 0.76x | 0.78x | 0.97x | 1.15x |
| Asset Growth % | -15.17% | 116.36% | 58.08% | 119.69% | 26.34% | 16.31% | -9.51% | 1.57% | -8.94% |
| Total Current Liabilities | 36.09M | 66.29M | 99.4M | 103.85M | 131.86M | 165.29M | 195.26M | 247.05M | 242.72M |
| Accounts Payable | 5.15M | 6.82M | 17.75M | 17.8M | 28.03M | 55.73M | 49.59M | 44.73M | 47.07M |
| Days Payables Outstanding | 29.6 | 26.48 | 38.53 | 27.27 | 31.33 | 52.4 | 47.63 | 36.23 | 35.5 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40.67M | 19.47M |
| Deferred Revenue (Current) | 2.53M | 4.6M | 3.87M | 6.08M | 10.18M | 18.84M | 43.99M | 11.83M | 9.53M |
| Other Current Liabilities | 13.92M | 30.83M | 63.45M | 65.76M | 74.94M | 68.01M | 71.89M | 47.08M | 166.66M |
| Current Ratio | 1.78x | 2.83x | 2.78x | 6.14x | 6.15x | 5.14x | 3.83x | 2.93x | 2.55x |
| Quick Ratio | 1.03x | 2.53x | 2.28x | 5.52x | 5.63x | 4.47x | 3.02x | 2.33x | 2.02x |
| Cash Conversion Cycle | 196.07 | 120.6 | 114.96 | 130.47 | 102.79 | 104.33 | 155.59 | 129.44 | 121.16 |
| Total Non-Current Liabilities | 88.41M | 8.73M | 31.73M | 246.26M | 340.17M | 447.55M | 443.77M | 457.51M | 483.22M |
| Long-Term Debt | 76.54M | 0 | 0 | 202.98M | 281.47M | 283.23M | 285.04M | 308.27M | 425M |
| Capital Lease Obligations | 0 | 0 | 14.06M | 15.91M | 23.92M | 123.52M | 113.57M | 106.42M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 11.87M | 8.73M | 17.67M | 27.36M | 17.84M | 23.92M | 31.83M | 32.37M | 58.22M |
| Total Liabilities | 124.49M | 75.02M | 131.13M | 350.11M | 472.02M | 612.84M | 639.03M | 704.56M | 725.94M |
| Total Debt | 76.54M | 0 | 20.38M | 228.32M | 314.67M | 419.88M | 415.67M | 473.56M | 444.48M |
| Net Debt | 62.84M | -41.83M | -30.79M | 133.71M | 243.49M | 247.36M | 356.8M | 404.33M | 353.84M |
| Debt / Equity | - | - | 0.10x | 0.62x | 0.73x | 0.95x | 1.33x | 1.80x | 2.86x |
| Debt / EBITDA | - | - | - | 91.55x | 8.62x | - | - | - | - |
| Net Debt / EBITDA | - | - | - | 53.61x | 6.67x | - | - | - | - |
| Interest Coverage | -5.44x | -15.16x | -314.44x | -1.83x | 3.35x | -14.26x | -21.47x | -13.39x | -24.33x |
| Total Equity | -29.15M▲ 0% | 131.28M▲ 550.4% | 194.98M▲ 48.5% | 366.31M▲ 87.9% | 433.11M▲ 18.2% | 439.95M▲ 1.6% | 313.63M▼ 28.7% | 263.1M▼ 16.1% | 155.17M▼ 41.0% |
| Equity Growth % | -391.78% | 550.37% | 48.53% | 87.87% | 18.24% | 1.58% | -28.71% | -16.11% | -41.02% |
| Book Value per Share | -5.13 | 2.73 | 3.33 | 6.01 | 6.73 | 6.86 | 4.83 | 4.02 | 2.31 |
| Total Shareholders' Equity | -29.15M | 131.28M | 194.98M | 366.31M | 433.11M | 439.95M | 313.63M | 263.1M | 155.17M |
| Common Stock | 10K | 57K | 59K | 62K | 64K | 65K | 66K | 66K | 68K |
| Retained Earnings | -477.61M | -600.08M | -624.83M | -659.21M | -634.6M | -729.19M | -951.8M | -1.05B | -1.25B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -13K | 122K | 220K | -616K | -1.82M | 1.37M | -1.95M | 5.59M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TNDM Cash Flow Statement
Tandem Diabetes Care, Inc. (TNDM) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -66.14M | -8.32M | 41.91M | 24.67M | 111.36M | 50.46M | -31.81M | 24.23M | -9.72M |
| Operating CF Margin % | -61.46% | -4.52% | 11.57% | 4.95% | 15.85% | 6.3% | -4.25% | 2.58% | -0.96% |
| Operating CF Growth % | -8.11% | 87.42% | 603.74% | -41.13% | 351.41% | -54.68% | -163.03% | 176.16% | -140.13% |
| Net Income | -73.03M | -122.61M | -24.75M | -34.38M | 15.57M | -94.59M | -222.61M | -96.03M | -204.71M |
| Depreciation & Amortization | 6.87M | 5.82M | 6.07M | 10.45M | 13.85M | 14.33M | 15.71M | 16.61M | 13.84M |
| Stock-Based Compensation | 12.63M | 23.74M | 58.07M | 58.43M | 60.75M | 84.92M | 88.08M | 101.38M | 92.38M |
| Deferred Taxes | -187K | 0 | -25K | -2.13M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 3.7M | 76.27M | 14.89M | 28.88M | 6.82M | 50.46M | 104.69M | 14.04M | 111.81M |
| Working Capital Changes | -16.11M | 8.46M | -12.35M | -36.59M | 14.37M | -4.65M | -17.68M | -11.78M | -23.04M |
| Change in Receivables | -10.45M | -15.85M | -13.7M | -38.84M | -30.98M | -7.83M | 4.28M | -20.8M | -56.81M |
| Change in Inventory | -5.89M | 6.76M | -30.98M | -15.36M | -4.95M | -42.45M | -46.05M | 5.81M | 24.82M |
| Change in Payables | -1.95M | 1.64M | 8.91M | 1.12M | 10.28M | 24.49M | -4.86M | -2.39M | 2.23M |
| Cash from Investing | 2.78M | -90.74M | -56.95M | -296.06M | -186.88M | 33.17M | -85.74M | -23.48M | 72.88M |
| Capital Expenditures | -5.72M | -2.99M | -19.54M | -27.41M | -14.18M | -34.1M | -26.8M | -19.23M | -19.95M |
| CapEx % of Revenue | 5.31% | 1.62% | 5.39% | 5.49% | 2.02% | 4.26% | 3.58% | 2.05% | 1.97% |
| Acquisitions | 0 | 1.71M | 0 | 0 | 0 | -25.72M | -69.5M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 8.5M | -1.71M | 0 | -4.89M | -9.33M | -8.86M | 0 | -46.4M | -78.59M |
| Cash from Financing | 32.38M | 117.18M | 24.21M | 314.44M | 51.93M | 16.88M | 4.11M | 8.37M | -43.37M |
| Debt Issued (Net) | 0 | -87.71M | 0 | 278.69M | 0 | 0 | 0 | 44.91M | -40.76M |
| Equity Issued (Net) | 40.38M | 172.93M | 0 | 0 | 0 | 17.55M | 0 | -36.73M | -2.61M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -30M | 0 |
| Other Financing | -8M | 31.97M | 24.21M | 35.75M | 51.93M | -675K | 4.11M | 183K | 0 |
| Net Change in Cash | -30.98M▲ 0% | 18.13M▲ 158.5% | 9.35M▼ 48.4% | 43.44M▲ 364.6% | -23.43M▼ 153.9% | 101.34M▲ 532.5% | -113.65M▼ 212.2% | 10.37M▲ 109.1% | 21.4M▲ 106.4% |
| Free Cash Flow | -71.85M▲ 0% | -11.3M▲ 84.3% | 22.36M▲ 297.8% | -7.63M▼ 134.1% | 87.85M▲ 1252.1% | 16.37M▼ 81.4% | -58.61M▼ 458.1% | 4.99M▲ 108.5% | -29.67M▼ 694.1% |
| FCF Margin % | -66.78% | -6.15% | 6.17% | -1.53% | 12.5% | 2.04% | -7.84% | 0.53% | -2.92% |
| FCF Growth % | -2.5% | 84.27% | 297.83% | -134.09% | 1252.1% | -81.37% | -458.12% | 108.52% | -694.09% |
| FCF per Share | -12.66 | -0.23 | 0.38 | -0.13 | 1.37 | 0.26 | -0.90 | 0.08 | -0.44 |
| FCF Conversion (FCF/Net Income) | 0.91x | 0.07x | -1.69x | -0.72x | 7.15x | -0.53x | 0.14x | -0.25x | 0.05x |
| Interest Paid | 7.88M | 10.8M | 0 | 2.71M | 4.31M | 0 | 7.57M | 0 | 0 |
| Taxes Paid | 22K | 16K | 67K | 177K | 260K | 0 | 1.92M | 0 | 0 |
TNDM Key Ratios
Tandem Diabetes Care, Inc. (TNDM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -290.04% | - | -240.11% | -15.17% | -12.25% | 3.89% | -21.67% | -59.08% | -33.3% | -97.88% |
| Return on Invested Capital (ROIC) | -149.32% | -152.17% | -54.37% | -9.89% | -1.8% | 2.89% | -10.21% | -25.77% | -11.11% | -9.96% |
| Gross Margin | 28% | 40.98% | 48.85% | 53.6% | 52.23% | 53.53% | 51.54% | 49.18% | 52.07% | 52.31% |
| Net Margin | -99.05% | -67.87% | -66.69% | -6.83% | -6.89% | 2.21% | -11.81% | -29.77% | -10.21% | -20.17% |
| Debt / Equity | - | - | - | 0.10x | 0.62x | 0.73x | 0.95x | 1.33x | 1.80x | 2.86x |
| Interest Coverage | -13.62x | -5.44x | -15.16x | -314.44x | -1.83x | 3.35x | -14.26x | -21.47x | -13.39x | -24.33x |
| FCF Conversion | 0.73x | 0.91x | 0.07x | -1.69x | -0.72x | 7.15x | -0.53x | 0.14x | -0.25x | 0.05x |
| Revenue Growth | 15.65% | 27.72% | 70.88% | 97.05% | 37.68% | 40.89% | 14% | -6.68% | 25.74% | 7.93% |
TNDM SEC Filings & Documents
Tandem Diabetes Care, Inc. (TNDM) SEC filings — annual & quarterly reports (10-K, 10-Q)
TNDM Frequently Asked Questions
Tandem Diabetes Care, Inc. (TNDM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Tandem Diabetes Care, Inc. (TNDM) reported $1.01B in revenue for fiscal year 2025.
Tandem Diabetes Care, Inc. (TNDM) grew revenue by 7.9% over the past year. This is steady growth.
Tandem Diabetes Care, Inc. (TNDM) reported a net loss of $204.7M for fiscal year 2025.
Dividend & Returns
Tandem Diabetes Care, Inc. (TNDM) has a return on equity (ROE) of -97.9%. Negative ROE indicates the company is unprofitable.
Tandem Diabetes Care, Inc. (TNDM) had negative free cash flow of $29.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More TNDM
Tandem Diabetes Care, Inc. (TNDM) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates